21 April 2021
EMA/COMP/223759/2021
Human Medicines Division

Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation

April 2021

The Committee for Orphan Medicinal Products held its 232nd plenary meeting on 13-15 April 2021.

Orphan medicinal product designation

Positive opinions

The COMP adopted 17 positive opinions recommending the following medicines for designation as orphan medicinal products to the European Commission:

1. Opinions adopted at the second COMP discussion, following the sponsor's response to the COMP list of questions:

- Adeno-associated viral vector serotype 2.5T encoding the human cystic fibrosis transmembrane conductance regulator with a partial deletion in the R domain for treatment of cystic fibrosis, Raremoon Consulting Esp S.L.;
- 6-Amino-5-chloro-N-((1R)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl)-4-pyrimidinecarboxamide for treatment of glioma, Parexel International (Irl) Limited;
- Human IgG1 monoclonal antibody against alpha-synuclein for treatment of multiple system atrophy, H. Lundbeck A/S.

2. Opinions adopted at the first COMP discussion:

- 2-[4-[3-(Methylamino)-1-phenylpropoxy]phenyl]ethanol hydrochloride for treatment of fragile X syndrome, Connecta Therapeutics S.L.;
- 2-Amino-6-[(2S)-2-hydroxypropanoyl]-7,8-dihydro-1H-pteridin-4-one for treatment of hyperphenylalaninemia, PTC Therapeutics International Limited;
- Adeno-associated viral vector serotype 5 expressing the human Cone-Rod Homeobox gene for treatment of Leber's congenital amaurosis, Variant;

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

- Adeno-associated virus serotype 9 expressing the cDNA for human MECP2 for treatment of Rett syndrome, Novartis Gene Therapies EU Limited;
- Autologous mobilised peripheral blood-derived CD34+ cells transduced ex vivo with a self-inactivating lentiviral vector containing a normal version of the coding region of the IL2RG gene for treatment of X-linked severe combined immunodeficiency, Real Regulatory Limited;
- Begelomab for treatment of dermatomyositis, Adienne S.r.l.;
- Dantrolene sodium, hemiheptahydrate for treatment of malignant hyperthermia, Norgine B.V.;
- Eflornithine for treatment of neuroblastoma, Brancaster Pharma Ireland Limited;
- Elamipretide for treatment of Barth syndrome, Scendea (NL) B.V.;
- Macitentan for treatment of functional single ventricle congenital heart disease, Janssen-Cilag International N.V.;
- Melatonin for treatment of retinitis pigmentosa, Worphmed S.r.l.;
- Synthetic 2'-O-(2-methoxyethyl)-modified antisense oligonucleotide linked to a triantennary cluster of N-acetyl galactosamine sugars targeting transmembrane protease, serine 6 mRNA for treatment of beta thalassemia intermedia and major, Ionis Development (Ireland) Limited;
- Trehalose for treatment of amyotrophic lateral sclerosis, FGK Representative Service GmbH;
- Zanubrutinib for treatment of marginal zone lymphoma, BeiGene Ireland Limited.

3. Opinion following appeal procedures:

None

Public summaries of opinions will be available on the EMA website following adoption of the respective decisions on orphan designation[1] by the European Commission. Please also refer to the Community Register of orphan medicinal products for human use.

Negative opinion

1. Opinion adopted following the sponsor's response to the COMP list of questions:

None

2. Opinion following appeal procedures:

None

Lists of questions

The COMP adopted 6 lists of questions on initial applications. These applications will be discussed again at the next COMP meting prior to the adoption of an opinion.

Oral hearings

2 oral hearings took place.

[1] Details of all orphan designations granted to date by the European Commission are entered in the EU Register of Orphan Medicinal Products

Withdrawals of applications for orphan medicinal product designation

The COMP noted that 3 applications for orphan medicinal product designation were withdrawn by the sponsor before adoption of the COMP opinion.

Detailed information on the orphan designation procedures

The list of medicinal products for which decisions on orphan designation have been granted by the European Commission since the last COMP meeting is provided in Annex 1.

Re-assessment of orphan designation at time of marketing authorisation

(Article 5(12) (b) of Regulation (EC) No 141/2000 of the European Parliament and of the Council)

When a designated orphan medicinal product receives a positive opinion for marketing authorisation from EMA's Committee for Medicinal Products for Human Use (CHMP), the COMP has the responsibility to review whether or not the medicinal product still fulfils the designation criteria prior to the granting of a marketing authorisation.

1. Opinions adopted at time of CHMP opinion:

- Kaftrio (ivacaftor/tezacaftor/elexacaftor) – Type II variation, for the treatment of cystic fibrosis, Vertex Pharmaceuticals (Ireland) Limited (EU/3/18/2116). The opinion was adopted by written procedure after the March meeting.
- Kalydeco (ivacaftor) - Type II variation, for the treatment of cystic fibrosis, Vertex Pharmaceuticals (Ireland) Limited (EU/3/08/556). The opinion was adopted by written procedure after the March meeting.

2. Opinion following appeal procedures:

None

Details of the designated orphan medicinal products that have been subject of a new European Union (EU) marketing authorisation application since the last COMP monthly report are provided in Annex 2.

Details on the authorised orphan medicinal products can be found on the EMA website.

Other matters

The main topics addressed during the meeting related to:

- Protocol assistance advice

Upcoming meetings

- The 233rd meeting of the COMP will be held on 10-12 May 2021.

Note

This monthly report, together with other information on the work of the European Medicines Agency, can be found on the EMA website: www.ema.europa.eu

Enquiries to: AskEMA (https://www.ema.europa.eu/en/about-us/contact/send-question-european-medicines-agency)

Annex 1

Designations granted by the European Commission following COMP opinion on the fulfilment of the orphan designation criteria since last COMP plenary meeting

Please also refer to the Community Register of orphan medicinal product for human use.

The list includes designation decisions that were revised following the amendment of an existing designated condition (identified by * when applicable)

Active substance	Orphan indication	Sponsor	COMP opinion date	EC designation date
5-fluoro-4-(7'-fluoro-2'-methylspiro[cyclopentane-1,3'-indol]-5'-yl)-N-(5-(1-methylpiperidin-4-yl)pyridin-2-yl)pyrimidin-2-amine	Treatment of glioma	Rapport Global Strategic Services Ireland Limited	18 February 2021	26 March 2021
Adeno-associated virus serotype hu68 containing the human *GALC* gene	Treatment of Krabbe disease	Pharma Gateway AB	18 February 2021	26 March 2021
Alpelisib	Treatment of PIK3CA related overgrowth spectrum	Novartis Europharm Limited	18 February 2021	26 March 2021
Alpha-L-iduronidase fused to Fab fragment of a humanised monoclonal antibody targeting human transferrin receptor	Treatment of mucopolysaccharidosis type I	Artemida Pharma Europe Limited	18 February 2021	26 March 2021
Cevostamab	Treatment of multiple myeloma	Roche Registration GmbH	18 March 2021	13 April 2021

Ganglioside GM1	Treatment of amyotrophic lateral sclerosis	3R Pharma Consulting GmbH	18 March 2021	13 April 2021
Herpes simplex virus 1 expressing the human *CFTR* gene	Treatment of cystic fibrosis	IDEA Innovative Drug European Associates (Ireland) Limited	18 February 2021	26 March 2021
Ilixadencel	Treatment of gastrointestinal stromal tumours	Immunicum AB	18 February 2021	26 March 2021
Lefitolimod	Treatment of small cell lung cancer	Molecular Biology And Integral Biomathics	18 February 2021	26 March 2021
Lorcaserin hydrochloride	Treatment of Dravet syndrome	Premier Research Group S.L.	18 February 2021	26 March 2021
Messenger RNA encoding Cas9, single guide RNA targeting the human *TTR* gene	Treatment of ATTR amyloidosis	Voisin Consulting	18 February 2021	26 March 2021
S-[5-(omega-methoxypoly(oxyethylene)-2-oxopentyl)]-L-cysteinylglycyl-L-serinylglycylgylcyl-L-isoleucyl-L-lysyl-L-glutamyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-arginyl-L-phenylalanyl-L-isoleucyl-L-histyl-L-isoleucyl-L-valyl-L-glutaminyl-L-serinyl-L-isoleucyl-L-isoleucyl-L-	Treatment of cutaneous T-cell lymphoma	Almirall S.A.	18 March 2021	13 April 2021

asparaginyl-L-threonyl-L-serinamide, acetate salt				

Annex 2

Designated orphan medicinal products that have been subject of a new European Union marketing authorisation application under the centralised procedure since the last COMP monthly report

Please also refer to the Community Register of orphan medicinal products for human use.

Active substance	Designated orphan indication	Sponsor/applicant	EU designation number
None			